Genome Editing in Stem Cells Offers New Possibilities for Obesity Treatment Without Muscle Loss

In a groundbreaking study published in Nature Communications, researchers from the Beijing Institute of Stem Cells and Regeneration (BISCRM) and the Institute of Zoology (IOZ) have made significant progress in understanding the FTO gene, which plays a dual role in obesity and muscle development. Their findings could pave the way for improved treatments for obesity and diabetes, providing an alternative to current therapies that often lead to muscle loss.

The research focuses on the FTO gene variant known as rs9939609-A, which is associated with a heightened risk of obesity in nearly 45% of Europeans, 24% of Africans, 30% of East Asians, and 35% of South Asians. The study reveals that this genetic variant triggers a complex cellular response involving the H19 and IGF2 genes, initially promoting muscle development but ultimately leading to early stem cell exhaustion and signs of aging.

Interestingly, the researchers discovered that stem cells with this variant quickly differentiate into skeletal muscle tissue. However, they also develop insulin resistance when subjected to high-fat conditions, indicating that skeletal muscle may be significantly influenced by the FTO variant in terms of accelerated growth and aging.

This research alters the current understanding of type 2 diabetes development. Previous knowledge indicated that high insulin levels and reduced glucose clearance appear long before a diabetes diagnosis. The study introduces a new human tissue model, leveraging CRISPR genome editing, to explore how muscle cells in individuals with the rs9939609-A variant initiate these metabolic issues.

The implications of this research extend beyond basic science; it offers a foundation for developing CRISPR-based therapeutics and small molecules aimed at addressing obesity and its associated complications. As the search for effective obesity treatments continues, these findings could lead to new strategies that effectively manage fat reduction while simultaneously promoting muscle growth, a crucial balance in obesity management.

Further insights can be found in the original study: Lu Guang et al, An obesogenic FTO allele causes accelerated development, growth and insulin resistance in human skeletal muscle cells, Nature Communications (2025). DOI: 10.1038/s41467-024-53820-2